Author Correction: Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Résumé fourni par la source

The original version of this Article contained an error in Figure 3 , where due to a mix-up in labelling the results, the 0 h untreated images for MDA-T32 were duplicated and rearranged from the BHT-101 images shown in Figure 3 A, which led to incorrect results shown in Figure 3 D. The original Figure 3 and accompanying legend appear below. Fig. 3 Wound healing assays of ( A ) BHT-101 (ATC), ( B ) SW1736 (ATC), ( C ) 8305C (ATC) and ( D ) MDA-T32 (PTC) cells. Cells were treated with 50 nM and 100 nM of onalespib and 15 μM sorafenib. Left column: Bar chart of migrated distance over time. Middle: heat map over migrated distance; Right: Representative images of wound/gap of control, 15 μM sorafenib, 100 nM onalespib and the combination at 0, 6, and 12 h. Values ± SD of 3 independent experiments. Full size image

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.